Ascendis Pharma A/S

Ascendis Pharma Misses on EPS, Stock Down 5.52%

Ascendis Pharma reported a larger-than-expected loss per share for Q1-2022, leading to a stock decline of 5.52%. The lack of revenue figures and management commentary adds uncertainty about the company's performance and future outlook. Investors may be cautious given the missed EPS expectations.